Codex DNA manufactures and sells laboratory equipment, synthetic biology instruments, reagents and associated products and related services, to pharmaceutical and academic laboratories worldwide. Co. has developed and commercialized products that include BioXp systems, including its BioXp 3250 system, BioXp kits for generating an array of synthetic DNA and mRNA, and benchtop reagents that complement the automated synthetic biology workflow applications and workflow solutions. Co. provides workflow solutions for the following areas: synthetic DNA for antibody and protein engineering of biologic drugs; synthetic DNA for genome editing; and synthetic DNA for metabolic pathway engineering The DNAY stock yearly return is shown above.
The yearly return on the DNAY stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DNAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
|